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treated with the high-affinity tissue angio-
tensin-converting enzyme (ACE) inhibitor
quinaprilat had significantly better recov-
ery of regional wall motion, a lower inci-
dence of ventricular arrhythmias, and a
smaller infarct size than controls. When the
low-affinity tissue ACE inhibitor enalapri-
lat was administered, the decrease in infarct
size was less (24% enalaprilat vs 14%
quinaprilat; P  .0001). The beneficial ef-
fects of quinaprilat’s action could be ex-
plained by its superior preservation of en-
dothelial function, since quinaprilat-treated
hearts had significantly greater coronary
arterial relaxation in response to bradykinin
(66% quinaprilat vs 32% enalaprilat; P 
.0001). When the bradykinin antagonist
HOE140 was added to the quinaprilat-
treated hearts, the protective effect on en-
dothelial function was abolished and these
hearts had a significant increase in infarct
size (48% quinaprilat  HOE vs 14%
quinaprilat; P  .0001).
I agree that ACE inhibitors enhance
myocardial protection during cardioplegic
arrest. However, ACE inhibitors are not all
equally protective. ACE inhibitors with
high tissue ACE inhibition such as
quinaprilat result in better preservation of
endothelial function, which decreases isch-
emic necrosis. This improvement in endo-
thelial function appears to be bradykinin-
mediated. I concur with Korn and
coworkers that high-affinity tissue ACE in-
hibitors may play an important role in en-
hancing cardioplegic protection during cor-
onary revascularization.2,3
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Tracheal replacement
To the Editor:
It is encouraging that efforts continue to
produce a “tissue-engineered trachea.”1
since this is about the only technique of the
many attempts at tracheal replacement by a
variety of approaches over more than 50
years that seems to offer any real promise.2
I question, however, whether the experi-
ments reported succeeded in forming “the
structural component of a functional tra-
cheal replacement.”
Although visually resembling a trachea,
the construction described failed to func-
tion (in sheep) over 5 and 7 days in 2
animals (with resultant malacia) or longer
than 2 days in 4 animals (with stenosis).
The authors’ findings suggest that inflam-
matory response might be responsible for
degeneration of the graft. Cell density and
hydroxyproline content support this hy-
pothesis. Conversion toward scar probably
had begun, even with survival of some
cartilage. The authors also allude to future
advisability of assuring blood supply,
which may indeed be a critical factor in this
early deterioration of the implant. One of
the keys to failure, even of autotrans-
planted free tracheal segments of any sig-
nificant length, has been failure of blood
supply, despite muscular or omental
pedicles. Very short tracheal grafts, of
course, are of no potential clinical use.
A subject that is deferred by the authors
to later experimentation, perhaps with en-
gineered epithelium, is the lack of epithe-
lial coverage in these experiments. In time
this would lead to graft obstruction by cic-
atrization. Epithelium in general has failed
to recolonize any extended length of tra-
cheal replacement by ingrowth from the
normal tracheal ends alone.
I shall look forward with interest to
future reports by this and other groups us-
ing tissue engineering in an effort to meet
the challenge of fashioning a usable tra-
cheal prosthesis for the rare occasion when
it is indeed needed.
Hermes C. Grillo, MD
Division of Thoracic Surgery
Massachusetts General Hospital
32 Fruit St
Boston, MA 02114
References
1. Kojima K, Bonassar LJ, Roy AK, Vacanti
CA, Cortiella J. Autologous tissue-engi-
neered trachea with sheep nasal chondro-
cytes. J Thorac Cardiovasc Surg. 2002;123:
1177-84.
2. Grillo HC. Tracheal replacement: a critical
review. Ann Thorac Surg. 2002;73:1995-
2004.
doi:10.1067/mtc.2003.260
Cardiac herniation after
intrapericardial pneumonectomy
To the Editor:
The brief communication by Baisi and as-
sociates1 reporting a case of cardiac herni-
ation after intrapericardial pneumonectomy
is almost identical with a case report in
another journal.2 Both reports fail to men-
tion that chest tubes were deployed after
the pneumonectomy. (They can clearly be
seen in their respective illustrations.)
The previous case2,3 instigated a spir-
ited correspondence4,5 centering on the
role, if any, of chest tubes after pneumo-
nectomy and their relation to cardiac her-
niation. The current case also fails to men-
tion a chest tube in the left posterior
thoracic gutter clearly seen on the com-
puted tomographic scan (see Figure 1). No
mention is made of its presence or mode of
use. Rather the authors emphasize (without
justification or substantiation in my mind)
that the induction chemotherapy was to
blame. Actually the initial closure of the
postpneumonectomy pericardial defect
failed because the sutures, placed under
tension, cut through—a mechanical prob-
lem, not a neoplastic or chemotherapeutic
problem.
The empty postpneumonectomy space
is not to be equated with that containing
variable amounts of lung tissue, which re-
quire chest tubes attached to suction. Using
such continued suction in a postpneumo-
nectomy space even for a short period of
time is to court disaster produced by exces-
sive mediastinal shift and, in some cases,
cardiac herniation. Despite the opinion of
Walker4 of the hazards of chest tubes after
pneumonectomy, Cooley5 expressed it well
when he said that he routinely used tubes
after pneumonectomy but that “when not in
use the tube should be clamped.” [italics
mine.]
Paul A. Kirschner, MD, FACS
Department of Cardiothoracic Surgery
Box 1028
Mount Sinai Medical Center
1 Gustave L. Levy Place
New York, NY 10029
Letters to the Editor
The Journal of Thoracic and Cardiovascular Surgery ● Volume 125, Number 4 975
